GPN Vaccines is a private biotechnology company developing a vaccine against Streptococcus pneumoniae
(the pneumococcus) – the world’s foremost bacterial pathogen. S. pneumoniae
is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 98 different serotypes of Streptococcus pneumoniae
and the best vaccine currently on the market only protects against 13 of them. Gamma-PNTM
– GPN Vaccines’ new S. pneumoniae
vaccine is being developed to protect children and adults against all S. pneumoniae
strains, regardless of strain serotype.